在吉林省公共资源交易中心，吉林省银河制药的牛黄上清丸（规格：6g×10丸）挂网价格为198元/盒。 该药品的省内价差倍数为10.88倍。实际上，该公司同规格的牛黄上清丸在淘宝、京东等平台，价格普 遍仅为5元/盒。 该公司六味地黄丸（规格：9g×10丸）情况类似，在吉林省公共资源交易中心的挂网价格也为198元/ 盒，省内价差倍数为61.88倍。而该公司同规格的六味地黄丸在电商平台的价格平均为5—6元/盒。 今年7月起，全国多个省份的政府采购平台或药械采购平台发布通知，对部分价格虚高的中成药和化药 价格进行治理，要求企业主动规范价格行为，将挂网价格调整至合理价格水平。 针对药品挂网价格治理，《中国经营报》记者联系了价差突出的部分企业，不过截至发稿未获回应。 部分企业降价超90% 今年7月22日，吉林省公共资源交易中心发布了《关于开展部分未过评药品和中成药挂网价格治理工作 的通知》，52个中成药被列入"部分价格虚高中成药产品列表"，43个化学药被列入"部分价格虚高未过 评药品列表"。 "部分价格虚高中成药产品列表"显示，重庆希尔安药业的元胡止痛片（规格：0.25g×36片）挂网价格为 110元，该药品每日费用为45 ...

Core Viewpoint - The article discusses the ongoing price governance of traditional Chinese medicine (TCM) products across multiple provinces in China, highlighting the significant price discrepancies and the government's efforts to regulate these prices to alleviate the financial burden on patients and the healthcare system [2][3][5][21]. Group 1: Price Governance Initiatives - Multiple provinces, including Guangxi, Liaoning, Heilongjiang, and Tianjin, have announced price governance measures for TCM products, indicating a nationwide effort to address high prices [2][3]. - The National Healthcare Security Administration (NHSA) has issued a report identifying TCM products with prices significantly higher than the lowest available options, prompting provincial authorities to take action [15][16]. Group 2: Price Discrepancies - There are extreme price differences for the same TCM products across different regions, with some products priced over 100 times higher than the lowest price available [6][9][10][11][12]. - For example, in Ningxia, a single unit of An Gong Niu Huang Wan is priced at 998 yuan, which is 11 times the lowest daily treatment cost for the same product [8]. Group 3: Factors Contributing to Price Variability - Price differences can be attributed to variations in ingredients, dosage forms, quality standards, and insufficient market competition, leading to concentrated pricing power among certain manufacturers [13]. - The complexity of TCM formulations and the lack of standardized quality control further exacerbate pricing issues [24]. Group 4: Impact on Pharmaceutical Companies - The price governance measures affect various pharmaceutical companies, including both small enterprises and established publicly listed firms like Tai Chi Group and Huason Pharmaceutical [21]. - Companies are under pressure to adjust their pricing strategies in response to the new regulations, with some indicating that the impact on their operations will be minimal [22]. Group 5: Patient Benefits and Future Outlook - The governance is expected to reduce the financial burden on patients, particularly for commonly used medications for chronic diseases, promoting fairer pricing and rational drug use [23]. - Experts suggest that while price governance is a step forward, it may not fully resolve the issue of price discrepancies, and additional measures such as collective procurement and improved industry standards are necessary [24].

Core Insights - The Xichuan Advanced Manufacturing Development Zone has been recognized as a digital transformation promotion center in Henan Province due to its solid digital infrastructure and innovative transformation practices [1] Group 1: Digital Transformation and Industry Focus - The development zone covers an area of 13.03 square kilometers and hosts 184 enterprises, focusing on digital transformation in four major industry clusters: automotive parts, modern traditional Chinese medicine, new energy, and new materials [1] - The automotive parts industry, led by Xijian, includes 86 associated enterprises with a market share of 20%, primarily producing shock absorbers and various components [2] - The modern traditional Chinese medicine industry, led by Fusen Pharmaceutical, comprises 35 associated enterprises, with market shares of 35.5% for oral solutions and 91.6% for injection solutions of the same product [2] Group 2: Innovation and Support Policies - The development zone has implemented policies to support technological innovation, allocating 50 million yuan in special funds for enterprises, with the automotive parts sector receiving 60 million yuan in provincial R&D support [3] - The area has established a national-level enterprise technology center, three nationally recognized laboratories, and numerous provincial-level centers, with 38 high-tech enterprises and 21 specialized enterprises [3] Group 3: Infrastructure and Investment - The development zone employs a "management committee + company" model for financing and has developed industrial parks for automotive parts, rural revitalization, and immigration, with 390,000 square meters of standardized factories built [4] - In 2024, the 86 large-scale industrial enterprises in the development zone are projected to achieve a total output value of 7.2 billion yuan, accounting for 90% of the county's industrial output, with an industrial added value of 1.83 billion yuan [4]